ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Wells, Gardner, Brennan Lead Surgical Oncology; Young, Flynn, Are New officers For Head & Neck

March 26, 1993

Data-Dredging? Don’t Try It, FDA Says.

May 11, 2007

Chemo+Radiation Preserves Voice, RTOG Study Finds

December 26, 2003

DCPC Advisers Ok Four New Grant Programs To Foster Prevention

May 22, 1992

PLCO Data Confirm Importance Of Regular Colorectal Cancer Screening, NCI Says

July 25, 2003

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013